Health Catalyst (HCAT) Stock Forecast & Price Target

HCAT Forecast - Frequently Asked Questions

What is Health Catalyst's forecast for 2026?

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Health Catalyst is $2.80, with a high forecast of $5.00 and a low forecast of $1.00.

Should I buy or sell Health Catalyst stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Health Catalyst in the last year. There is currently 1 sell rating, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HCAT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HCAT, but not buy additional shares or sell existing shares.

Does Health Catalyst's stock price have much upside?

According to analysts, Health Catalyst's stock has a predicted upside of 75.26% based on their 12-month stock forecasts.

What analysts cover Health Catalyst?

Health Catalyst has been rated by research analysts at Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Raymond James Financial, Stephens, Stifel Nicolaus, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Health Catalyst more than its competitors?

Analysts like Health Catalyst less than other "medical" companies. The consensus rating score for Health Catalyst is 2.23 while the average consensus rating score for "medical" companies is 2.30. Learn more on how HCAT compares to other companies.